Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy and Safety of HAIC With FOLFOX vs Sorafenib for Patients Who Showed TACE-resistant: a Retrospective Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with HCC according to the European Association for the Study of the Liver (EASL) diagnostic criteria~* TACE failure/refractoriness by Liver Cancer Study Group of Japan (LCSGJ) criteria~* Without extrahepatic metastasis~* The following laboratory parameters:~Platelet count ≥ 60,000/μL Hemoglobin ≥ 8.5 g/dL Total bilirubin ≤ 1.5 mg/dL Serum albumin ≥ 35 g/L ASL and AST ≤ 5 x upper limit of normal Serum creatinine ≤ 1.5 x upper limit of normal INR ≤ 1.5 or PT/APTT within normal limits Absolute neutrophil count (ANC) \>1,500/mm3~Exclusion Criteria:~* Known history of HIV~* History of organ allograft~* Patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry.~* Serious non-healing wound, ulcer, or bone fracture~* Evidence of bleeding diathesis.~* Any other hemorrhage/bleeding event \> CTCAE Grade 3 within 4 weeks of first dose of study drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- HAIC of FOLFOX (Type: EXPERIMENTAL): Retreatment With hepatic arterial infusion chemotherapy of oxaliplatin , fluorouracil, and leucovorin
- Sorafenib (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).